Literature DB >> 18777956

Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.

James W Hodge1, Chandan Guha, Jacques Neefjes, James L Gulley.   

Abstract

The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. Evidence suggests that immunotherapy is most beneficial alone when employed early in the disease process or in combination with standard therapies (eg, radiation) later in the disease process. Indeed, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. As monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in crosspriming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses. Learning how to exploit radiation-induced changes to tumor-cell antigens, and how to induce effective immune responses to these cumulatively immunogenic stimuli, is an exciting frontier in cancer therapy research. This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well as preclinical systems demonstrating that immunotherapy can be effectively combined with radiation therapy. Finally, we review current clinical trials where standard-of-care radiation therapy is being combined with immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777956      PMCID: PMC3474236     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  39 in total

1.  Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo.

Authors:  Jason M Grayson; Laurie E Harrington; J Gibson Lanier; E John Wherry; Rafi Ahmed
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

2.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

3.  Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.

Authors:  Kwan-Hwa Chi; Shih-Jen Liu; Chung-Pin Li; Hsu-Ping Kuo; Yu-Shan Wang; Yee Chao; Shih-Liang Hsieh
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

4.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

5.  Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.

Authors:  S M Scholl; J M Balloul; G Le Goc; N Bizouarne; C Schatz; M P Kieny; S von Mensdorff-Pouilly; A Vincent-Salomon; L Deneux; E Tartour; W Fridman; P Pouillart; B Acres
Journal:  J Immunother       Date:  2000 Sep-Oct       Impact factor: 4.456

Review 6.  Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer.

Authors:  R E Roses; M Xu; G K Koski; B J Czerniecki
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

7.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 8.  153Sm-EDTMP for bone pain palliation in skeletal metastases.

Authors:  Carlo L Maini; Serenella Bergomi; Luisa Romano; Rosa Sciuto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

9.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  54 in total

1.  Is the induction of tumor cell senescence the key to a good irradiated tumor vaccine?

Authors:  Michael P Brown
Journal:  Mol Ther       Date:  2012-05       Impact factor: 11.454

Review 2.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

3.  Complement-dependent modulation of antitumor immunity following radiation therapy.

Authors:  Michelle Elvington; Melissa Scheiber; Xiaofeng Yang; Katherine Lyons; Dustin Jacqmin; Casey Wadsworth; David Marshall; Kenneth Vanek; Stephen Tomlinson
Journal:  Cell Rep       Date:  2014-07-24       Impact factor: 9.423

4.  Therapeutic vaccines: the ultimate personalized therapy?

Authors:  James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

5.  Vaccines as monotherapy and in combination therapy for prostate cancer.

Authors:  Julia Rotow; Sofia R Gameiro; Ravi A Madan; James L Gulley; Jeffrey Schlom; James W Hodge
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

6.  A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.

Authors:  James L Gulley; Ravi A Madan; Kwong-Yok Tsang; Philip M Arlen; Kevin Camphausen; Mahsa Mohebtash; Mitchell Kamrava; Jeffrey Schlom; Deborah Citrin
Journal:  Expert Opin Biol Ther       Date:  2011-08-28       Impact factor: 4.388

7.  Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.

Authors:  M Kamrava; Kwong Y Tsang; R A Madan; A Kaushal; C N Coleman; J Gulley
Journal:  Clin Dev Immunol       Date:  2010-03-08

Review 8.  Promising novel immunotherapies and combinations for prostate cancer.

Authors:  Philip M Arlen; Mahsa Mohebtash; Ravi A Madan; James L Gulley
Journal:  Future Oncol       Date:  2009-03       Impact factor: 3.404

Review 9.  Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy.

Authors:  Max M Wattenberg; Ahmed Fahim; Mansoor M Ahmed; James W Hodge
Journal:  Radiat Res       Date:  2014-06-24       Impact factor: 2.841

Review 10.  Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.

Authors:  B Harpreet Singh; James L Gulley
Journal:  Ther Adv Vaccines       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.